JP2014207903A5 - - Google Patents

Download PDF

Info

Publication number
JP2014207903A5
JP2014207903A5 JP2014083444A JP2014083444A JP2014207903A5 JP 2014207903 A5 JP2014207903 A5 JP 2014207903A5 JP 2014083444 A JP2014083444 A JP 2014083444A JP 2014083444 A JP2014083444 A JP 2014083444A JP 2014207903 A5 JP2014207903 A5 JP 2014207903A5
Authority
JP
Japan
Prior art keywords
cancer
vector
pharmaceutical composition
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014083444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014207903A (ja
JP5767733B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014207903A publication Critical patent/JP2014207903A/ja
Publication of JP2014207903A5 publication Critical patent/JP2014207903A5/ja
Application granted granted Critical
Publication of JP5767733B2 publication Critical patent/JP5767733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014083444A 2007-02-28 2014-04-15 ブラキュリポリペプチドおよび使用方法 Active JP5767733B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90423607P 2007-02-28 2007-02-28
US60/904,236 2007-02-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009551830A Division JP5596980B2 (ja) 2007-02-28 2008-02-27 ブラキュリポリペプチドおよび使用方法

Publications (3)

Publication Number Publication Date
JP2014207903A JP2014207903A (ja) 2014-11-06
JP2014207903A5 true JP2014207903A5 (enExample) 2015-05-14
JP5767733B2 JP5767733B2 (ja) 2015-08-19

Family

ID=39650527

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009551830A Active JP5596980B2 (ja) 2007-02-28 2008-02-27 ブラキュリポリペプチドおよび使用方法
JP2014083444A Active JP5767733B2 (ja) 2007-02-28 2014-04-15 ブラキュリポリペプチドおよび使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009551830A Active JP5596980B2 (ja) 2007-02-28 2008-02-27 ブラキュリポリペプチドおよび使用方法

Country Status (7)

Country Link
US (3) US8188214B2 (enExample)
EP (3) EP2444410A3 (enExample)
JP (2) JP5596980B2 (enExample)
AU (1) AU2008221383B2 (enExample)
CA (1) CA2678404C (enExample)
DK (1) DK2918598T3 (enExample)
WO (1) WO2008106551A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013014457A8 (pt) 2010-12-09 2017-12-19 Pasteur Institut usos da enzima 6-metilguanina-dna-metiltrasferase (mgmt, ec 2.1.1.63) para aumentar a produção de proteína heteróloga, bem como vetor de expressão, células recombinantes e polipeptídeo de fusão compreendendo sinal de secreção peptídica e proteína snap
AU2012228937B2 (en) * 2011-03-17 2016-11-03 Globeimmune, Inc. Yeast-Brachyury immunotherapeutic compositions
EP2895191B1 (en) * 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
WO2014043535A1 (en) * 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
WO2014186047A1 (en) * 2013-03-19 2014-11-20 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
KR102565284B1 (ko) 2015-07-31 2023-08-08 버베리안 노딕 에이/에스 폭스바이러스에서 발현을 증강하기 위한 프로모터
WO2017023840A1 (en) * 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
CN116196403A (zh) 2015-08-03 2023-06-02 美国卫生和人力服务部 Brachyury缺失突变体、编码该缺失突变体的非酵母载体及其用途
EP3400009A2 (en) 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
CA3026345A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
WO2017210562A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
CA3063087A1 (en) 2017-05-09 2018-11-15 Julius Y. STRAUSS Combination pdl1 and tgf-beta blockade in patients with hpv+ malignancies
CN114829882B (zh) 2019-11-05 2023-02-28 阿比尔技术公司 植物产品中感染的预测
WO2022187963A1 (en) * 2021-03-10 2022-09-15 Provincial Health Services Authority Immunotherapy agents targeting brachyury and methods of using same

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
EP0256654B1 (en) 1986-07-07 1996-09-18 Centocor, Inc. Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
EP0299108B1 (en) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
CA1340203C (en) 1987-09-16 1998-12-15 Noboru Yanagida Recombinant apivoxvirus
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
US5543508A (en) 1987-12-15 1996-08-06 Gene Shears Pty. Limited Ribozymes
JP2955759B2 (ja) 1988-07-20 1999-10-04 セゲブ・ダイアグノスティックス・インコーポレイテッド 核酸配列を増幅及び検出する方法
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
WO1991019803A1 (en) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
DE69225710T3 (de) 1991-07-25 2004-10-14 Idec Pharmaceuticals Corp., San Diego Anregung von antworten zytotoxischer t-lymphozyten
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
AU687736B2 (en) 1992-05-11 1998-03-05 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5902880A (en) 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
WO1996002668A1 (en) 1994-07-15 1996-02-01 Azco Nobel N.V. Use of rna polymerase to improve nucleic acid amplification process
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
JP3907698B2 (ja) 1994-10-03 2007-04-18 アメリカ合衆国 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
EP0814184A4 (en) 1995-02-14 1999-04-14 Chisso Corp BIODEGRADABLE FIBER AND NONWOVEN TEXTILE
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
AU727308B2 (en) 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
GB0023203D0 (en) * 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
CA2301166A1 (en) 1997-07-24 1999-02-04 Yuan-Peng Zhang Liposomal compositions for the delivery of nucleic acid catalysts
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
AU1606799A (en) * 1997-12-09 1999-06-28 Virogenetics Corporation Recombinant vaccinia constructs expressing feline il-2, compositions and methodsof use thereof
EP1038016A2 (en) 1997-12-16 2000-09-27 Valentis Inc. Needle-free injection of formulated nucleic acid molecules
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
US6849255B2 (en) * 1998-08-18 2005-02-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for enhancing cartilage repair
ATE370234T1 (de) 1998-09-01 2007-09-15 Us Gov Health & Human Serv Page-4, ein gage-ähnliches gen auf dem x- chromosom das von neoplastischer prostata, testis und uterus exprimiert wird, und dessen anwendungen
BR9914116A (pt) * 1998-09-30 2002-01-15 Corixa Corp Composições e métodos para imunoterapia especìfica de wt1
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
EP1159441B8 (en) 1999-03-10 2008-10-29 Marie Curie Cancer Care Delivery of nucleic acids and proteins to cells
AU781925B2 (en) 1999-07-13 2005-06-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The T-cell receptor gamma alternate reading frame protein, (TARP) and uses thereof
AU7361900A (en) 1999-09-10 2001-04-10 Fordham University Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
EP1278541A1 (en) * 2000-04-28 2003-01-29 The Government of The United States of America, as represented by The Department of Health and Human Services Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
WO2002078516A2 (en) * 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
CA2449042A1 (en) * 2001-05-30 2002-12-27 Biomedical Center In silico screening for phenotype-associated expressed sequences
EP2233572A3 (en) * 2002-06-06 2011-01-12 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
AU2003295328A1 (en) * 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20090144209A1 (en) * 2004-07-07 2009-06-04 Nec Corporation Sequence prediction system
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes

Similar Documents

Publication Publication Date Title
JP2014207903A5 (enExample)
JP2018148890A5 (enExample)
CA2741724C (en) Promoters for recombinant viral expression
KR102684237B1 (ko) 개인 맞춤형 백신
JP7050044B2 (ja) ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター
FI3352776T3 (fi) Htt-repressoreita ja niiden käyttötapoja
WO2017209053A1 (ja) 新規な遺伝子組換えワクシニアウイルス
JP2020530303A (ja) Ｃａｒ ｔ細胞標的を発現する腫瘍溶解性ウイルス、及びその使用
CN109844104B (zh) 重组疫苗病毒及其用途
SG10201809075XA (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
JP2010259446A5 (enExample)
JP2016510989A5 (enExample)
JP2010519904A5 (enExample)
JP2019535311A5 (enExample)
JP2018521651A5 (enExample)
JP2019500907A5 (enExample)
RU2019112725A (ru) Композиции и способы для повышения стабильности трансгенов в поксвирусах
US20160010064A1 (en) Mutant vaccinia virus strains, uses thereof and method of producing the same
CN103484462B (zh) Survivin启动子调控CD基因的重组腺病毒载体构建及其应用
Lousberg et al. Innate immune recognition of poxviral vaccine vectors
JP2025500867A (ja) 前立腺癌ワクチン及びその使用
HK1211622B (zh) 突变型痘苗病毒株、其用途及其制造方法
WO2025157196A1 (zh) 经修饰的痘苗病毒及其用途
RU2678056C1 (ru) Рекомбинантный онколитический штамм вируса осповакцины Л-ИВП_oncoB, содержащий гены, кодирующие гранулоцитарно-макрофагальный колониестимулирующий фактор и полиэпитопный иммуноген, состоящий из эпитопов антигенов, гиперэкспрессирующихся опухолевыми клетками при раке молочной железы
Selmi Precision Neurology in Multiple Sclerosis: Contemporary Advances and Future Perspectives